First Advanced Oral Treatment For Asthma - Sanofi's Investigational Drug Shows Potential [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
Two doses of rilzabrutinib, 800 mg daily and 1200 mg daily, were studied. The data showed that treatment with oral rilzabrutinib at both high and low doses led to a numerical reduction in loss of asthma control (LOAC) events (the primary endpoint) and improvements in symptoms in adult patients with uncontrolled moderate-to-severe asthma. These results were presented at the 2024 American Thoracic Society (ATS) International Conference in San Diego and will support the phase 3 program, in which a twice-daily dose of rilzabrutinib will be studied for moderate-to-severe asthma. In this proof-of-concept study, treatment with high and low doses of rilzabrutinib resulted in a 36% and 25% relative risk reduction in loss of asthma control (LOAC) events, respectively, at week 12 (primary endpoint). Significant and clinically meaningful improvements in asthma symptoms were also observed with a -0.54/-0.59 LS mean difference in the asthma control questionnaire. Rilzabrutinib high and l
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Sanofi: A Leader In Life-Saving Vaccines And Treatments [Seeking Alpha]Seeking Alpha
- Is It Too Late to Buy Novavax Stock? [Yahoo! Finance]Yahoo! Finance
- Exploring Dividend Stocks On Euronext Paris Featuring Exacompta Clairefontaine And Two Others [Yahoo! Finance]Yahoo! Finance
- Cancer Immunotherapy market is projected to grow at a CAGR of 12.6% by 2034: Visiongain [Yahoo! Finance]Yahoo! Finance
- Exploring Three Top Dividend Stocks On Euronext Paris [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 6/11/24 - Form 6-K
- 5/30/24 - Form 6-K
- 5/28/24 - Form 6-K
- SNY's page on the SEC website